AI-Powered IVF Robotics Hub Coming to East Dallas

Overture Life is opening its Dallas facility to serve as its U.S. clinical operations headquarters and run non-invasive embryo assessment testing that helps clinicians select embryos for in vitro fertilization.

The Madrid-based biotechnology firm integrates artificial intelligence and robotics to expand access, improve precision, and increase efficiency in the IVF process. The company operates programs in Latin America and Europe and will move its U.S. hub from San Antonio to Dallas in the new year.

Overture Life’s CEO Hans Gangeskar is based in Virginia, and the company also has operations in Palo Alto, California, and Spain. The lawyer and software engineer says the move to Dallas, where the region’s growing biotech industry employs 27,000 professionals across 850 companies, is about talent and connectivity. “The most important thing for this facility is lab talent that knows how to run these machines in a lab facility and a local regulatory climate where inspectors will come quickly when you need them to inspect something,” he says. “Dallas is a good regulatory environment, and the talent for running a lab like this is very much there. With us being based in Virginia, Palo Alto, and Madrid, they all have many non-stop flights a day from Dallas, which is a huge help for us.”

The company uses AI to automate IVF platforms, increasing capacity and patient access to IVF, where the U.S. is far behind Europe. Clinicians can run about 900 IVF cycles per million women in the U.S., while Europe’s capacity averages over 3,000 IVF cycles per million women. Overture’s goal is to increase capacity and reduce wait times for those wanting to grow their families via IVF. The Dallas facility will be focused on analyzing the fluid surrounding stored embryos to guide fertility physicians and embryologists in the IVF process without an invasive biopsy.

Demand is building for DaVitri, Overture’s automated egg-freezing system that uses robotic precision to achieve a 12 percent improvement in egg survival rates while increasing clinic capacity by 300 percent without adding staff. The company also uses robotics to improve outcomes by automating the egg fertilization process, which can vary widely between labs and professionals. That system, called ICSI.A, helped deliver the world’s first babies born from robotic sperm injection in 2024. Overture’s IVF platforms are currently operating in clinics in Brazil, Argentina, Chile, Bolivia, Panama, Turkey, and New Jersey. The firm is collaborating with clinics across Texas and the nation to advance full FDA approval of its platforms.

By the end of January, Overture will occupy 4,501 square feet of the Bogart Building on Ross in East Dallas, where the company will make a multi-million-dollar investment in the space to bring it up to lab standards and install the necessary equipment, electrical capacity, and ventilation. The Google Ventures-backed biotech firm will be hiring positions ranging from product development and clinical operations to laboratory operations, manufacturing, and regulatory affairs.

Converting what was once an office into lab space is a growing trend in North Texas, notably via the renovation of the former EDS headquarters in Plano as part of the Texas Research Quarter development from NexPoint. “The infrastructure we’re establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States,” says Hafsa Irfan, Overture Life’s head of clinical operations for the Dallas facility.

Gangeskar says Overture Life’s move to Dallas is about expanding capacity and access to IVF, one of the most intimate and expensive medical procedures that families experience. “You don’t need to talk to a lot of people to realize that it’s hard to get into an IVF clinic. There’s a waiting list, and it’s very expensive,” he says. “We need to build a lot of new clinics and increase capacity in those clinics.”